CN101180070A - 降钙素在治疗炎性疾病状况中作为组合治疗的应用 - Google Patents

降钙素在治疗炎性疾病状况中作为组合治疗的应用 Download PDF

Info

Publication number
CN101180070A
CN101180070A CNA2006800137667A CN200680013766A CN101180070A CN 101180070 A CN101180070 A CN 101180070A CN A2006800137667 A CNA2006800137667 A CN A2006800137667A CN 200680013766 A CN200680013766 A CN 200680013766A CN 101180070 A CN101180070 A CN 101180070A
Authority
CN
China
Prior art keywords
calcitonin
thr
gly
leu
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800137667A
Other languages
English (en)
Chinese (zh)
Inventor
伊恩·麦金太尔
莫罗·佩雷蒂
露西娅·曼奇尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary and Westfiled College University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary and Westfiled College University of London filed Critical Queen Mary and Westfiled College University of London
Publication of CN101180070A publication Critical patent/CN101180070A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CNA2006800137667A 2005-04-01 2006-03-30 降钙素在治疗炎性疾病状况中作为组合治疗的应用 Pending CN101180070A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0506708.7A GB0506708D0 (en) 2005-04-01 2005-04-01 Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
GB0506708.7 2005-04-01

Publications (1)

Publication Number Publication Date
CN101180070A true CN101180070A (zh) 2008-05-14

Family

ID=34586589

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800137667A Pending CN101180070A (zh) 2005-04-01 2006-03-30 降钙素在治疗炎性疾病状况中作为组合治疗的应用

Country Status (13)

Country Link
US (1) US20080160025A1 (https=)
EP (1) EP1868627B1 (https=)
JP (2) JP2008534566A (https=)
KR (1) KR20080017001A (https=)
CN (1) CN101180070A (https=)
AU (1) AU2006228334A1 (https=)
BR (1) BRPI0612220A2 (https=)
CA (1) CA2603156A1 (https=)
GB (1) GB0506708D0 (https=)
IL (1) IL186286A0 (https=)
MX (1) MX2007012078A (https=)
RU (1) RU2394591C2 (https=)
WO (1) WO2006103455A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071410A1 (en) 2010-09-21 2012-03-22 Unigene Laboratories Inc. Calcitonin products and therapies for treating inflammatory or degenerative diseases
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
RU2668125C2 (ru) * 2013-03-27 2018-09-26 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4006269A1 (de) * 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
UA41909C2 (uk) * 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
CA2381425A1 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7329750B2 (en) * 2003-06-30 2008-02-12 Merck & Co., Inc. 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BINSTOCK M L: "effect of calcitonin and glucocorticoids in combination on the hyper calcemia of malignancy", 《ANNALS OF INTERNAL MEDICINE》 *
赵学伟等: "糖皮质激素引发骨质疏松的机理及对策", 中国医院药学杂志 *

Also Published As

Publication number Publication date
EP1868627B1 (en) 2014-10-15
WO2006103455A2 (en) 2006-10-05
CA2603156A1 (en) 2006-10-05
US20080160025A1 (en) 2008-07-03
KR20080017001A (ko) 2008-02-25
EP1868627A2 (en) 2007-12-26
WO2006103455A3 (en) 2007-03-01
RU2394591C2 (ru) 2010-07-20
GB0506708D0 (en) 2005-05-11
RU2007139888A (ru) 2009-05-10
JP2008534566A (ja) 2008-08-28
AU2006228334A1 (en) 2006-10-05
JP2013032360A (ja) 2013-02-14
BRPI0612220A2 (pt) 2010-10-26
MX2007012078A (es) 2008-02-22
IL186286A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
CA2781576C (en) Combination preparation including a corticosteroid and exosomes
EP4358995B1 (en) A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
BR112012029986B1 (pt) Anticorpo humano isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente ou bloqueia a atividade biológica de gdf8 humano maduro do tipo selvagem, composição farmacêutica e usos dos mesmos
JP2025138661A (ja) Ｆｃｒｎ抗体およびその使用の方法
BR122022025353B1 (pt) Composição e uso de conjugado de derivado de oxintomodulina para a prevenção ou tratamento de hiperlipidemia, doença hepática gordurosa ou arteriosclerose
CN106232141A (zh) 针对由给予类固醇诱发的生长不足的药物
BR112017004739B1 (pt) Ligantes de hormônio folículo estimulante, complexo de ligante e gonadotrofina, uso de um ligante, e composição farmacêutica
WO2020034941A1 (zh) 抗IL-1β的抗体、其药物组合物及其用途
KR20190002563A (ko) 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR20150109386A (ko) 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체
JP2023061978A (ja) ｈＧＨ融合タンパク質を含有する、成長ホルモン欠乏症を治療するための医薬組成物
JP2022023216A (ja) ビメンチン由来のペプチドに特異的に結合する物質を含む皮膚疾患の予防及び治療用組成物
CN110139672A (zh) 运动调节功能提高剂
CN118055767A (zh) 新颖的组合施用
JP2022501319A (ja) 抗Ｓｉｇｌｅｃ抗体、それを備える薬学的組成物及びその使用
JP2013032360A (ja) 炎症性疾患状態の処理のための併用治療療法としてのカルシトニンの使用
KR20180135839A (ko) hGH 융합단백질을 포함하는 성장호르몬 결핍을 치료하기 위한 약학 조성물
KR102953072B1 (ko) 난소 및 난자의 성숙 및/또는 발달을 위한 조성물 및 이의 용도
US8192736B2 (en) Remedy for endometriosis
EP4397762A1 (en) Anti-growth hormone antibody
WO2024123822A1 (en) Recombinant antibody, pharmaceutical composition comprising the same, and uses thereof in treating cancers
CN119548621A (zh) 抗igf-1r抗体或其抗原结合部分在减重中的应用
KR20260036536A (ko) 다발성 경화증 치료를 위한 조성물 및 방법
HK40103690A (zh) 新颖的组合施用
EA050428B1 (ru) АНТИТЕЛА ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20080514